🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

149 results for “recombinant” Clear

  1. Recombinant human growth hormone

    United Therapeutics Europe Ltd

    Gulf War Syndrome

    phase 2 small molecule active

    1 trial

  2. Recombinant human heparan N-sulfatase (rhHNS)

    Takeda

    Mucopolysaccharidosis (MPS)

    phase 2 mab completed

    1 trial

  3. Recombinant human heparan N-sulfatase [rhHNS]

    Takeda

    Sanfilippo Syndrome

    phase 2 small molecule completed

    1 trial

  4. Recombinant human hyaluronidase + immune globulin intravenous

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 mab completed

    1 trial

  5. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 2 small molecule completed

    1 trial

  6. Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

    The First People's Hospital of Lianyungang

    Hematological Malignancy

    phase 2 small molecule active

    1 trial

  7. Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP), Lyophilized powder for reconstitution, Voxzogo 1.2 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Idiopathic Short Stature (ISS)

    phase 2 small molecule active

    1 trial

  8. Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP)

    BioMarin Pharmaceutical Australia Pty Ltd

    Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome

    phase 2 small molecule active

    1 trial

  9. activated recombinant human factor VII

    Novo Nordisk A/S

    Acquired Bleeding Disorder

    phase 2 small molecule completed

    2 trials

  10. low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  11. recombinant human Angiostatin protein

    CASI Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  12. recombinant human endostatin

    Peking University Third Hospital

    Melanoma

    phase 2 small molecule active

    1 trial

  13. recombinant human erythropoietin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypoxic-Ischemic Encephalopathy

    phase 2 small molecule completed

    1 trial

  14. recombinant human erythropoietin (rhEpo)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Infant, Premature

    phase 2 small molecule active

    1 trial

  15. recombinant human growth hormone

    Affiliated Hospital of Jiangnan University

    Phelan-McDermid Syndrome

    phase 2 small molecule completed

    1 trial

  16. recombinant humanized anti-CD25 monoclonal antibody

    The First People's Hospital of Lianyungang

    Transfusion Dependent Thalassemia

    phase 2 small molecule active

    1 trial

  17. 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HPV Infection

    phase 1 mab completed

    1 trial

  18. Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumor

    phase 1 small molecule active

    1 trial

  19. PEGylated recombinant candida urate oxidase

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule active

    1 trial

  20. PEGylated recombinant human hyaluronidase PH20

    HALOZYME THERAPEUTICS, INC.

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  21. PEGylated recombinant human interferon alpha-2b injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis B, Chronic

    phase 1 small molecule active

    1 trial

  22. Pegylated Recombinant Candida Utilis Uricase for Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule active

    1 trial

  23. RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

    Rocket Pharmaceuticals B.V.

    Dilated Cardiomyopathy (DCM)

    phase 1 gene therapy active

    1 trial

  24. Recombinant ADAMTS13

    Takeda

    Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources